In Situ Hybridization Global Market Report 2024

The in situ hybridization market has grown strongly in recent years. It will grow from $1.57 billion in 2023 to $1.72 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The expansion observed in the historical period can be attributed to factors such as the early adoption in research, the evolution of molecular biology tools, the development of diagnostic applications, a shift in the focus of biomedical research, and the increasing investment in biotechnology.

The in situ hybridization market is expected to see strong growth in the next few years. It will grow to $2.51 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The anticipated growth in the forecast period can be attributed to the increasing adoption in clinical diagnostics, a rise in research and development funding, the implementation of automation and high-throughput solutions, and expanded applications in neuroscience and pathology. Key trends expected in the forecast period involve advancements in molecular biology, a growing demand in research applications, the expansion of diagnostic applications, an increased demand for personalized medicine, and a rise in funding in biomedical research.

The anticipated rise in infectious diseases is set to drive the growth of the in-situ hybridization market. Infectious diseases, which spread through contaminated foods, beverages, and pathogens such as viruses, bacteria, fungi, and parasites, contribute to the increasing demand for in-situ hybridization (ISH). ISH involves the use of labeled nucleic acid sequences (probes) specific to the infectious organism to identify complementary nucleic acid sequences in the tissue. For instance, the Annual Epidemiological Report for 2021 from the European Centre for Disease Prevention and Control reported an increase in hepatitis C cases and rates in Germany, reaching 4,718 cases and 5.7 rates from 4,536 cases and 5.5 rates. Therefore, the growth of infectious diseases is a driving force behind the expansion of the in-situ hybridization market.

The upsurge in cancer cases is anticipated to fuel the growth of the in-situ hybridization market. In-situ hybridization is employed to identify specific genetic alterations in cancer cells, including gene amplifications, deletions, translocations, and rearrangements. According to the American Cancer Society (ACS), it is projected that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. Hence, the increasing incidence of cancer is a significant factor contributing to the growth of the in-situ hybridization market.

Technological advancements represent a prominent trend in the in-situ hybridization market. Major companies in this market are concentrating on the development of technologies to enhance their market position. For instance, in April 2021, Bio-Techne Corporation introduced the RNAscope technology and DNAscope Assays. RNAscope is an enhanced in-situ hybridization (ISH) technique that enables the direct visualization of single-molecule transcription with single-cell resolution in unaltered cells and tissues. DNAscope utilizes the proven 'double-Z' probe design and signal enhancement system of RNAscope to create probes for any DNA target swiftly and easily, allowing target visualization in formalin-fixed paraffin-embedded (FFPE) tissues.

Major companies operating in the in-situ hybridization market are driving profitability through innovative product solutions, such as Hybridization Chain Reaction RNA Chromogenic in situ Hybridization (HCR RNA-CISH). HCR RNA-CISH is a technique that facilitates the visualization of RNA molecules in cells and tissues with high resolution and sensitivity. In February 2023, Molecular Instruments (MI) launched HCR RNA-CISH to enhance automated chromogenic in-situ hybridization workflows, providing better performance than existing approaches with reduced turnaround time and cost. It also features native support for Immunohistochemistry (IHC) codetection and full compatibility with major automation platforms.

In September 2021, PerkinElmer Inc., a US-based life science company, acquired BioLegend for $5.25 billion. This strategic acquisition aims to leverage PerkinElmer's extensive life science platform and global infrastructure to support BioLegend in expanding its business in the diagnostic segment. The acquisition is expected to broaden PerkinElmer’s life science offerings, encompassing cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing. BioLegend, based in the US, specializes in the manufacturing of diagnostic reagents for biomedical research companies.

Major companies operating in the in situ hybridization market report are Thermo Fisher Scientific Inc., Bio SB Inc., BioGenex Laboratories, Advanced Cell Diagnostics Inc., Exiqon A/S, Agilent Technologies Inc., F. Hoffmann-La Roche AG, Abbott Laboratories Inc., Merck KGaA, PerkinElmer Inc., Biocare Medical LLC, Genemed Biotechnologies, Danaher Corporation, Leica Biosystems Nussloch GmbH, Bio-Rad Laboratories Inc., Oxford Gene Technology, Abnova Corporation, Qiagen, Bio-Techne Corporation, Biochain Institute Inc., Cytocell Ltd., Enzo Life Sciences Inc., Eurofins Scientific SE, FISH Technologies Sdn Bhd, Genetix Biotech Asia Pvt. Ltd., Zytomed System GmbH, AdvanDx Inc., Affymetrix Inc., Akoya Biosciences Inc., Becton Dickinson and Company (BD), Cell Signaling Technology Inc., DAKO Systemtechnik und Service GmbH & Co, Life Technologies, Molecular Devices LLC., NanoString Technologies Inc., Visiopharm A/S.

North America was the largest region in the in situ hybridization market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global in situ hybridization market duirng the forecast period. The regions covered in the in situ hybridization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in situ hybridization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of in-situ hybridization products include analytical instruments, kits and reagents, software and services, among others. Analytical instruments are designed to assist researchers in detecting and visualizing specific nucleic acid sequences within cells or tissues. Various techniques involved in this process include fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH), which utilize different types of probes such as DNA and RNA. These techniques find applications in diverse areas, including cancer research, cytogenetics, developmental biology, infectious diseases, and more. The end users of these products include research and diagnostic laboratories, contract research organizations (CROs), academic institutes, and others.

The in situ hybridization market research report provides in situ hybridization market statistics, including in situ hybridization industry global market size, regional shares, competitors with an in situ hybridization market share, detailed in situ hybridization market segments, market trends and opportunities, and any further data you may need to thrive in the in situ hybridization industry. This in situ hybridization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The In-situ hybridization market includes revenues earned by entities by providing in-situ hybridization with synthetic oligonucleotides probes, double-stranded DNA (dsDNA) probes, and single-stranded DNA (dsDNA) probes. The market value includes the value of related goods sold by the service provider or included within the service offering. The In-situ hybridization market also includes sales of linear hybridization chain reaction techniques and non-linear hybridization chain reaction techniques. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.